Grünenthal eyes Cialis rights acquisition in LATAM boost

Grünenthal Group, a German pharmaceutical giant known for its pain management solutions, has announced its acquisition of the commercial rights to Cialis® for Mexico, Brazil, and Colombia from Eli Lilly and Company. This strategic move aims to strengthen Grünenthal's presence in Latin America and bolster its commercial footprint in the Men's Health segment. Cialis® is used for the treatment of erectile dysfunction and benign prostatic hyperplasia. Starting from this acquisition, Grünenthal plans to transition the manufacturing of Cialis to its site in Santiago, Chile, a process expected to close in the third quarter of 2025 pending customary conditions. This transaction highlights Grünenthal's continued strategy of acquiring established medications, expanding its portfolio, and enhancing profitability. Since 2017, Grünenthal has already invested over €2 billion in similar transactions, including acquiring rights to Nebido®, Crestor®, and Nexium®. Grünenthal CEO, Gabriel Baertschi, emphasized the acquisition as a crucial step in their targeted acquisition strategy to expand existing portfolios and serve its existing customer base in key Latin American markets.